Clinical trial NCT01372956: Cholesterol Goal Attainment Rate and Its Associated Factors Among Dyslipidemic Patients on Lipid-lowering Drug Therapy in Korea
Official title: Cholesterol Goal Attainment Rate and Its Associated Factors Among Dyslipidemic Patients on Lipid-lowering Drug Therapy in Korea (CRESCENDO)
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Dyslipidemia
Keywords: LDL-C, cholesterol, risk factor
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2011-06-14
Enrollment: 4950
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Primary Care

Brief summary: This is a multi-centre, cross-sectional, chart review study to investigate cholesterol goal attainment rates defined by modified NCEP-ATP III guidelines and define its possible determinants among Korean dyslipidemic patients

Detailed description: MC MD

Eligibility criteria: Inclusion Criteria:

* Patient who has a dyslipidemia with a lipid profile result within 3 months
* Patient who has a dyslipidemia without change of lipid lowering drug dosage during 3 months after lipid profile test.

Exclusion Criteria:

* Patient who involved in this study previously.
* Patient who participated in other clinical study with study drug within 90 days.

Primary outcomes:
measure: Cholesterol goal attainment rate according to NCEP-ATP III guideline
timeFrame: Once, at enrollment
Secondary outcomes:
measure: Factors for cholesterol goal achievement: Age, Family history, smoking history, waist circumstance, etc.
timeFrame: Once, at enrollment
measure: Cholesterol goal attainment rate related to CHD or disease history
timeFrame: Once, at enrollment
Other outcomes:
Locations:
city: Cheongju
country: Korea, Republic of
facility: Research Site
state: Chungcheongbuk-do
city: Cheonan
country: Korea, Republic of
facility: Research Site
state: Chungcheongnam-do
city: Tae
country: Korea, Republic of
facility: Research Site
state: Chungcheongnam-do
city: Anyang
country: Korea, Republic of
facility: Research Site
state: Gyeonggi-do
city: Bucheon
country: Korea, Republic of
facility: Research Site
state: Gyeonggi-do
city: Bundang
country: Korea, Republic of
facility: Research Site
state: Gyeonggi-do
city: Goyang
country: Korea, Republic of
facility: Research Site
state: Gyeonggi-do
city: Guri
country: Korea, Republic of
facility: Research Site
state: Gyeonggi-do
city: Uijeongbu
country: Korea, Republic of
facility: Research Site
state: Gyeonggi-do
city: Gwangju
country: Korea, Republic of
facility: Research Site
state: Jeollabuk-do
city: Iksan
country: Korea, Republic of
facility: Research Site
state: Jeollabuk-do
city: Chuncheon
country: Korea, Republic of
facility: Research Site
state: Kangwon-do
city: Daegu
country: Korea, Republic of
facility: Research Site
state: Kyeongsangbuk-do
city: Deagu
country: Korea, Republic of
facility: Research Site
state: Kyeongsangbuk-do
city: Busan
country: Korea, Republic of
facility: Research Site
state: Kyeongsangnam-do
city: Changwon
country: Korea, Republic of
facility: Research Site
state: Kyeongsangnam-do
city: Busan
country: Korea, Republic of
facility: Research Site
city: Gwangju
country: Korea, Republic of
facility: Research Site
city: Incheon
country: Korea, Republic of
facility: Research Site
city: Seoul
country: Korea, Republic of
facility: Research Site
Study officials:
affiliation: Samsung Medical Center
name: Jeong Ui Park
role: PRINCIPAL_INVESTIGATOR
affiliation: Seoul National University Hospital
name: Jong sung Kim
role: PRINCIPAL_INVESTIGATOR
affiliation: Kangbuk Samsung Hospital
name: Sung woo Park
role: PRINCIPAL_INVESTIGATOR
References: